Recurrence of mogamulizumab-associated rash in patients with relapsed erythrodermic cutaneous T-cell lymphoma after retreatment with mogamulizumab

This is the authors' abstract. We don't add key points for this paper.

Mycosis fungoides (MF), and the leukemic variant Sézary syndrome (SS) are the most common types of cutaneous T-cell lymphomas (CTCL) characterized by a chronic course with limited therapeutic options for advanced stages of disease.1 Mogamulizumab (moga) is a monoclonal antibody therapy with enhanced antibody-dependent cellular cytotoxicity activity against the C-C motif chemokine receptor 4 receptor that is expressed on malignant T cells, facilitating their migration to the skin.2 Moga was Food and Drug Administration approved in 2018 for relapsed/refractory MF and SS.